Clinical Trial Update: IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients [EARLY_Phase 1]

View source ↗

Summary

Early-phase (Phase 1) trial update for IM19 CAR-T cell therapy in IgA nephropathy and membranous nephropathy; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy
• Membranous Nephropathy

Drugs mentioned

• IM19 CAR-T Cell Therapy

Snippet

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Conditions: IgA Nephropathy, Membranous Nephropathy | EARLY_Phase 1 | Status: NOT_YET_RECRUITING